JP2001247459A5 - - Google Patents

Download PDF

Info

Publication number
JP2001247459A5
JP2001247459A5 JP2000232871A JP2000232871A JP2001247459A5 JP 2001247459 A5 JP2001247459 A5 JP 2001247459A5 JP 2000232871 A JP2000232871 A JP 2000232871A JP 2000232871 A JP2000232871 A JP 2000232871A JP 2001247459 A5 JP2001247459 A5 JP 2001247459A5
Authority
JP
Japan
Prior art keywords
compound
medicament
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000232871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001247459A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2001247459A publication Critical patent/JP2001247459A/ja
Publication of JP2001247459A5 publication Critical patent/JP2001247459A5/ja
Pending legal-status Critical Current

Links

JP2000232871A 2000-03-03 2000-08-01 癌の組み合わせ療法 Pending JP2001247459A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ50319900 2000-03-03
NZ503199 2000-03-03

Publications (2)

Publication Number Publication Date
JP2001247459A JP2001247459A (ja) 2001-09-11
JP2001247459A5 true JP2001247459A5 (https=) 2006-12-07

Family

ID=19927770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000232871A Pending JP2001247459A (ja) 2000-03-03 2000-08-01 癌の組み合わせ療法

Country Status (2)

Country Link
US (1) US6667337B2 (https=)
JP (1) JP2001247459A (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
ES2252160T3 (es) * 2001-08-30 2006-05-16 Cancer Research Technology Limited Combinaciones anticancerosas de dmxaa y paclitaxel o docetaxel.
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CA2523178C (en) * 2003-03-24 2012-10-23 Luitpold Pharmaceuticals, Inc. Materials and methods to potentiate cancer treatment
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
US20060148674A1 (en) * 2004-12-31 2006-07-06 Luduena Richard F Therapeutic composition
CA2620436A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
WO2010040112A2 (en) 2008-10-03 2010-04-08 Curna, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
CN102361985B (zh) 2008-12-04 2017-06-20 库尔纳公司 通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
ES2600781T3 (es) 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
RU2620970C2 (ru) 2008-12-04 2017-05-30 КьюРНА,Инк., Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
WO2010093904A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
CA2755404C (en) 2009-03-17 2020-03-24 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
KR101722541B1 (ko) 2009-05-06 2017-04-04 큐알엔에이, 인크. Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
ES2618572T3 (es) 2009-05-08 2017-06-21 Curna, Inc. Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CA2762987A1 (en) 2009-05-22 2010-11-25 Joseph Collard Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
ES2629339T3 (es) 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
CA2765700C (en) 2009-06-16 2021-01-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CN102482672B (zh) 2009-06-26 2016-11-09 库尔纳公司 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
ES2585360T3 (es) 2009-08-05 2016-10-05 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
ES2599986T3 (es) 2009-08-11 2017-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
CN102482670B (zh) 2009-08-21 2018-06-15 库尔纳公司 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
EP2470657B1 (en) 2009-08-25 2019-10-23 CuRNA, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
DK2480669T3 (en) 2009-09-25 2018-02-12 Curna Inc TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
CA2782366A1 (en) 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
RU2619185C2 (ru) 2009-12-23 2017-05-12 Курна, Инк. Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
NO2516648T3 (https=) 2009-12-23 2018-04-07
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
US8962585B2 (en) 2009-12-29 2015-02-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
DK2519632T3 (en) 2009-12-31 2018-07-23 Curna Inc TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
KR101853509B1 (ko) 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
KR101854926B1 (ko) 2010-01-11 2018-05-04 큐알엔에이, 인크. 성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
DK2529015T3 (en) 2010-01-25 2018-02-26 Curna Inc TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
RU2608496C2 (ru) 2010-02-22 2017-01-18 Курна, Инк. Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
KR101900962B1 (ko) 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
RU2018110642A (ru) 2010-05-03 2019-02-27 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799207C (en) 2010-05-26 2019-03-26 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
JP5917497B2 (ja) 2010-05-26 2016-05-18 カッパーアールエヌエー，インコーポレイテッド メチオニンスルホキシドレダクターゼａ（ｍｓｒａ）に対する天然アンチセンス転写物の阻害によるｍｓｒａ関連疾患の治療
WO2011163499A2 (en) 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
ES2640755T3 (es) 2010-10-06 2017-11-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
ES2657590T3 (es) 2010-11-23 2018-03-06 Curna, Inc. Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
EP2718439B1 (en) 2011-06-09 2017-08-09 CuRNA, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
KR101991980B1 (ko) 2011-09-06 2019-06-21 큐알엔에이, 인크. 소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2672101B2 (ja) * 1986-12-23 1997-11-05 ディーエフシー ニュージーランド リミテッド キサンテノン−４−酢酸誘導体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB9308166D0 (en) 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
EP0743064A1 (en) 1995-05-17 1996-11-20 Eli Lilly And Company Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
US5977077A (en) 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
AU5792398A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Leukotriene antagonists for treatment or inhibition of gout
US5817684A (en) 1996-12-13 1998-10-06 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
AU6570798A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating gingivitis
WO1998042335A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating gout
US5914340A (en) 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
AU6764798A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
AU6572298A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
HUP9904672A2 (hu) 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
US5998454A (en) 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
WO2000010600A2 (en) 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
JP4638098B2 (ja) 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
PL355172A1 (en) 1999-11-11 2004-04-05 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy

Similar Documents

Publication Publication Date Title
JP2001247459A5 (https=)
JP2004505047A5 (https=)
JP2001247459A (ja) 癌の組み合わせ療法
JP2010270124A5 (https=)
JP2003514935A5 (https=)
JP2006508091A5 (https=)
JP2006528700A5 (https=)
JP2005526107A5 (https=)
JP2006526590A5 (https=)
JP2005537234A5 (https=)
JP2010523477A5 (https=)
JP2004517098A5 (https=)
JP2004517843A5 (https=)
JP2012513390A5 (https=)
JP2003522198A5 (https=)
EP1125936A3 (en) Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases
JP2015508068A5 (https=)
CA2425218A1 (en) Pharmaceutical solutions of modafinil compounds
JP2004510816A5 (https=)
JP2002535370A5 (https=)
JP2009517411A5 (https=)
JP2004500406A5 (https=)
JP2002506864A5 (https=)
RU99128033A (ru) Способ и композиции для перорального введения таксанов
RU2005129333A (ru) 4-[(2,4-дихлор-5-метоксифенил)амино]-6-алкокси-3-хинолинкарбонитрилы для лечения ишемического повреждения